Loading quotes...
Forecast
The analysts' average price target is €19.07 (+390.23%). The median is €19.07 (+390.23%).
| Buy |
Â
2 |
| Hold |
Â
5 |
| Sell |
Â
1 |
Discussions in the community
Translated from German
Delisting CurevacHi, I didn't realize that I had to take action myself to exchange my Curevac shares for Biontech. There was no notification from TRADE REPUBLIC either. Then yesterday I got this message! Do you have…
WW Wolf W. II in Schnack
0 6Translated from German
TTWROR negative despite successful investment and two-month holding periodI tried to use an older post for this, but I noticed that the thread doesn't get bumped back to the top… so here's a new topic. I'm really stuck on this one... Out of boredom, I entered a few older…
RP910 IV in Schnack
0 4
News Go to news feed
Curevac closure threatens hundreds of job losses in TĂĽbingen
After the announcement to close the Curevac site, hundreds of employees face deep cuts; the works council expects about two-thirds of jobs to disappear by the end of 2026 and says operational activity is to be stopped on December 31. A taskforce appointed by the state government aims to secure infrastructure and know-how and to offer staff prospects, while Biontech emphasizes a socially acceptable reduction of personnel and support programs. The works council criticizes the management’s limited willingness to negotiate and points out that there are hardly any comparable jobs in the region for highly specialized professionals. » More on finanzen.net
Curevac founder accuses Biontech of deception after announced factory closures
Ingmar Hoerr sharply criticizes Biontech and calls the takeover of Curevac a "dumb sale", saying that, according to him, jobs are to be cut and production sites in Marburg, Idar‑Oberstein, Singapore and Tübingen are to be closed. He accuses Biontech of using the takeover primarily to acquire patents and to eliminate a competitor. Hoerr warns that knowledge built up over decades will be lost and at the same time criticizes Biontech's share buyback program as contradictory to the stated reasons for cost cutting. » More on welt.de
Curevac founder accuses Biontech of deception after announced site closures
After the takeover of Curevac, founder Ingmar Hoerr accuses Biontech of deception after Biontech announced the closure of several sites, including Tübingen. Around 820 former Curevac employees are affected; up to 1,860 positions could be cut across the group. Biontech justifies the measures with overcapacity and cost reductions, while the union and Tübingen’s mayor sharply criticize and speculate about patent strategies and the prioritization of financial interests. » More on faz.net
CureVac founder accuses BioNTech of deception after takeover and plant closures
After BioNTech's takeover of CureVac, founder Ingmar Hoerr criticizes the company over planned closures, particularly the Tübingen site, calling it deception and suggesting possible circumvention of patent disputes. BioNTech justifies the closures with excess capacity, low utilization and cost cutting; up to 1,860 jobs could be affected worldwide. Unions describe the move as socially irresponsible, while BioNTech simultaneously announces a multi-billion euro share buyback program; the stock fell in response. » More on finanzen.net
Curevac sues Moderna over patent infringement on mRNA technology
Curevac filed a lawsuit against Moderna in a U.S. federal court in Delaware, accusing the company of infringing several Curevac patents used to stabilize mRNA in its COVID-19 vaccine Spikevax. The Tübingen-based company is seeking damages in the form of licensing fees on Spikevax sales and has named eight U.S. patents. Curevac was acquired by Biontech last year; Biontech is pursuing its own separate lawsuit against Moderna. Moderna said it intends to defend itself vigorously. » More on manager-magazin.de
Financials
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 54.13m | - |
| Gross profit | 53.76m | - |
| Net profit | 273.23m | - |
| EBITDA | 317.86m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €952.7m |
Number of shares | 225.17m |
52-week high/low | €5.19 - €2.25 |
| Dividends | No |
Beta | 1.84 |
P/E ratio | 4.45 |
PEG ratio | 0.32 |
P/B ratio | 1.09 |
P/S ratio | 17.19 |
Company profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in TĂĽbingen, Germany.
| Name | CureVac |
| CEO | Alexander Zehnder |
| Headquarters | TĂĽbingen,
Netherlands |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 14/08/2020 |
| Employees | 825 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CVAC |
XETRA | 5CV.F |
XETRA | 5CV.DE |
Frankfurt | 5CV.F |
DĂĽsseldorf | 5CV.DU |
Hamburg | 5CV.HM |
Milan | 1CVAC.MI |
London | 0A9E.L |
SIX | 5CV.SW |
MĂĽnchen | 5CV.MU |
Wien | CVAC.VI |